Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Advances in hemophilia care: report of two symposia at the Hemophilia 2010 World Congress.

Dolan G, Cruz JA, Steinhagen-Thiessen E, Kessler C, Haaning J, Lemm G, Altisent C, Guerrero C, Hermans C, Riske B, Bolton-Maggs P.

Adv Ther. 2012 Apr;29 Suppl 1:1-16. doi: 10.1007/s12325-012-0010-3. Epub 2012 Mar 16.

PMID:
22467446
2.

The promise and challenges of bioengineered recombinant clotting factors.

Pipe SW.

J Thromb Haemost. 2005 Aug;3(8):1692-701. Review.

3.

Articular Bleeding in Hemophilia.

Rodriguez-Merchan EC.

Cardiovasc Hematol Disord Drug Targets. 2016;16(1):21-24. Review.

PMID:
28049407
4.

The hope and reality of long-acting hemophilia products.

Pipe SW.

Am J Hematol. 2012 May;87 Suppl 1:S33-9. doi: 10.1002/ajh.23146. Epub 2012 Mar 3. Review.

5.

Molecular approaches for improved clotting factors for hemophilia.

Kaufman RJ, Powell JS.

Blood. 2013 Nov 21;122(22):3568-74. doi: 10.1182/blood-2013-07-498261. Epub 2013 Sep 24. Review.

6.

Demographics of hemophilia in developing countries.

Evatt BL.

Semin Thromb Hemost. 2005 Nov;31(5):489-94. Review.

PMID:
16276455
8.

Pioneering designs for recombinant coagulation factors.

Schulte S.

Thromb Res. 2011;128 Suppl 1:S9-12. doi: 10.1016/S0049-3848(12)70003-8. Review.

PMID:
22221848
9.

Treatment of hemophilia.

Rodeghiero F.

Ric Clin Lab. 1985 Oct-Dec;15(4):289-303. Review.

PMID:
3914697
10.

Hemophilia in Iran.

Dorgalaleh A, Dadashizadeh G, Bamedi T.

Hematology. 2016 Jun;21(5):300-10. doi: 10.1080/10245332.2015.1125080. Epub 2016 Feb 24. Review.

PMID:
26914731
11.

FEIBA versus NovoSeven in hemophilia patients with inhibitors.

Franchini M, Coppola A, Tagliaferri A, Lippi G.

Semin Thromb Hemost. 2013 Oct;39(7):772-8. doi: 10.1055/s-0033-1354425. Epub 2013 Sep 8. Review.

PMID:
24014071
12.

How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.

Leissinger CA, Singleton T, Kruse-Jarres R.

Blood. 2015 Jul 9;126(2):153-9. doi: 10.1182/blood-2014-10-551952. Epub 2015 Mar 31. Review.

13.

Advances and dilemmas in recombinant blood products.

Schaefer J.

J Infus Nurs. 2002 Sep-Oct;25(5):305-9.

PMID:
12355055
14.

Management of joint bleeding in hemophilia.

Simpson ML, Valentino LA.

Expert Rev Hematol. 2012 Aug;5(4):459-68. Review.

PMID:
22992238
15.

Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia.

Witkop M, Guelcher C, Forsyth A, Hawk S, Curtis R, Kelley L, Frick N, Rice M, Rosu G, Cooper DL.

Am J Hematol. 2015 Dec;90 Suppl 2:S3-10. doi: 10.1002/ajh.24220.

16.

Advances in hemophilia and the role of current and emerging prophylaxis.

Acharya SS.

Am J Manag Care. 2016 Apr;22(5 Suppl):s116-25. Review.

17.
18.

Advances in hemophilia: experimental aspects and therapy.

Rodriguez NI, Hoots WK.

Hematol Oncol Clin North Am. 2010 Feb;24(1):181-98. doi: 10.1016/j.hoc.2009.11.003.

PMID:
20113902
19.

Hemophilia A.

Lusher JM, Warrier I.

Hematol Oncol Clin North Am. 1992 Oct;6(5):1021-33. Review.

PMID:
1400070
20.

Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.

Ay Y, Ersin T, Yesim O, Hilkay KT, Dilek I, Gulcihan O, Ahmet K.

Blood Coagul Fibrinolysis. 2016 Sep;27(6):729-31. doi: 10.1097/MBC.0000000000000366.

PMID:
26484639

Supplemental Content

Support Center